428 filings
Page 7 of 22
8-K
hwt4gg8
12 Nov 20
Hepion Pharmaceuticals to Present at The Liver Meeting Digital ExperienceTM 2020
9:33am
8-K
uexvy2
10 Nov 20
Hepion Pharmaceuticals Completes First Cohort Enrollment in Phase 2a 'AMBITION' Clinical Trial
10:33am
UPLOAD
fi05t bk1
5 Nov 20
Letter from SEC
12:00am
8-K
jbx0igr0qg
27 Oct 20
Other Events
9:45am
8-K
u0rrj1sf 6f
5 Oct 20
Announces Creation of Clinical Pharmacology Analytics Team
9:06am
8-K
6kefto 4qpup
1 Oct 20
Regulation FD Disclosure
4:27pm
8-K
j8co81 9o
29 Sep 20
Hepion Pharmaceuticals to Present at H.C. Wainwright's 4th Annual NASH Virtual Investor Conference
8:47am
8-K
fvvpph 1z
17 Sep 20
Other Events
12:40pm
8-K
34ou3bw8t7fz
1 Sep 20
Hepion Pharmaceuticals Completes Final Dosing in Phase 1b Multiple Ascending Dose Study of CRV431
1:27pm
8-K
aum 4hrcl
27 Aug 20
Other Events
11:19am
8-K
mzbg8 ydnbe
12 Aug 20
Hepion Pharmaceuticals Announces Publication of Preclinical Study Evaluating CRV431’s Antiviral Properties
8:46am
8-K
t9s6j
5 Aug 20
Hepion Pharmaceuticals Announces First NASH Patient Dosed with CRV431 in Phase 2 ‘AMBITION’ Clinical Trial
9:18am
8-K
f8549
31 Jul 20
Submission of Matters to a Vote of Security Holders
12:00am
8-K
l7mzr2hps50iaxx 1ll
7 Jul 20
Hepion Pharmaceuticals Announces Preclinical Data Supporting Novel Two-Pronged Approach to Treating COVID-19 with CRV431
8:26am
8-K
c0qdq 9ztv3u7vhtx
29 Jun 20
Hepion Pharmaceuticals Announces Advancement to Final Dose Level in Ongoing Multiple Ascending Dose Clinical Study of CRV431
12:00am
8-K
omg9j4t
22 Jun 20
Other Events
4:54pm